Rolapitant (INN, trade name Varubi in the US and Varuby in the European Union) is a drug originally developed by Schering-Plough and licensed for clinical development by Tesaro, which acts as a selective NK1 receptor antagonist (antagonist for the NK1 receptor). It has been approved as a medication for the treatment of chemotherapy-induced nausea and vomiting (CINV) after clinical trials showed it to have similar or improved efficacy and some improvement in safety over existing drugs for this application.
{{Drugbox | IUPAC_name = (5S,8S)-8-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}methyl)- 8-phenyl-1,7-diazaspiro[4.5]decan-2-one | image = Rolapitant (Patent Verified).svg | image_class = skin-invert-image | width = 225
| pronounce = | tradename = Varubi (US), Varuby (EU) | Drugs.com = | MedlinePlus = a615041 | DailyMedID = Rolapitant | pregnancy_AU = | pregnancy_US = N | pregnancy_category = | licence_EU = yes | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_US_comment = | legal_EU = Rx-only | routes_of_administration = By mouth (tablets), intravenous | ATC_prefix = A04 | ATC_suffix = AD14 | class = NK1 receptor antagonists, antiemetics
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).